BioMark Diagnostics Inc. (BUX.CN)
BioMark Diagnostics Inc. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Richmond, BC, CA. The stock last traded at $0.55, up 0.00% on the session, giving a market capitalisation of $57.8M. Its beta of -0.32 implies it has historically moved less than the broad market.
BioMark Diagnostics Inc. is an oncology specialist, developing advanced diagnostic tools for cancer to enable early detection, continuous patient monitoring, and the assessment of initial treatment efficacy. The firm holds a research partnership with the Icahn School of Medicine, collaborating on clinical trials specifically addressing the early identification of lung cancer. Founded in 2014, its corporate headquarters are situated in Richmond, Canada. BioMark Diagnostics Inc. operates as a subsidiary of Biomark Technologies Inc.
BioMark Diagnostics Inc. is most often compared with the following Healthcare names: